Event Panel Schedule

1573840800 - 1573845300
Clin­i­cal In­sights of New Rapid­ly Act­ing, NM­DA-based An­tide­pres­sants
1573846200 - 1573850700
NK cell ex­pan­sion and pro­lif­er­a­tion with PM21 par­ti­cles: ad­junc­tive ther­a­py for he­ma­topoi­et­ic stem cell tran­s­plan­ta­tion and po­ten­tial treat­ment for both liquid and solid tu­mors
1573851600 - 1573856100
Three clin­i­cal-stage cell ther­a­py pro­grams in dry age-re­lat­ed mac­u­lar de­gen­er­a­tion, spi­nal cord in­jury, and on­col­o­gy
1573857000 - 1573861500
SCLC: Re­cent ap­pro­vals in first and third line could be joined with Lur­binecte­din in 2nd line
1573862400 - 1573866900
On­co­lyt­ic ade­n­ovirus armed w im­mune sti­m­u­lat­ing trans­gene tar­get­ing bas­ket of I-O in­di­ca­tions
1573867800 - 1573868700
E-CEL® (En­gi­neered En­dothe­lial Cell) Ther­a­py and Vas­cu­lar Niche Bi­ol­o­gy
Export to Excel